Mobidiag secures 25m loan from EIB
Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1551 entries already.
Entries by Thomas Gabrielczyk
Philogen SpA raises 62m to push registration
/in News/by Thomas GabrielczykPrivately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured 62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III […]
Halt of Polyphor trial shrinks company valuation
/in News/by Thomas GabrielczykRoche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its […]
MS linked to epigenetic changes in immune cells
/in News/by Thomas GabrielczykEpigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Swiss Biotech Day 2019
/in News/by Thomas GabrielczykThe Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and […]
Confo Therapeutics raise 30m in Series A financing
/in News/by Thomas GabrielczykThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
Researchers report how body fat affects imune cells
/in News/by Thomas GabrielczykUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets 36.5m support from IMI
/in News/by Thomas GabrielczykThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
/in News/by Thomas GabrielczykTransgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgènes armed oncolytic immunotherapies.
Alentis Therapeutics debuts with CHF12.5m
/in News/by Thomas GabrielczykLiver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.